STOCK TITAN

DuPont Reports Second Quarter 2026 Results

(Moderate)
(Very Positive)
Tags

DuPont (NYSE: DD) reported second quarter 2026 net sales of $1.819 billion, up 4% year over year, with organic sales also up 4%. GAAP income from continuing operations was $191 million and operating EBITDA was $448 million, a 6% increase and a 24.6% margin.

GAAP EPS from continuing operations was $1.37, while adjusted EPS rose 48% to $1.88. Cash provided by operating activities from continuing operations was $400 million, driving transaction-adjusted free cash flow of $326 million and 127% conversion. DuPont plans a $250 million share repurchase in the third quarter and raised full-year 2026 guidance to net sales of $7.16–$7.19 billion, operating EBITDA of $1.75–$1.77 billion and adjusted EPS of $7.17–$7.32. The company also noted its 1-for-3 reverse stock split effective June 24, 2026, its completed $1.2 billion cash Aramids divestiture plus note and equity interests, and a GICS reclassification to Industrials effective July 31, 2026.

Loading...
Loading translation...

Positive

  • Net sales up 4% to $1.819 billion in Q2 2026
  • Adjusted EPS increased 48% year over year to $1.88
  • Operating EBITDA rose 6% to $448 million; margin expanded 40 bps to 24.6%
  • Transaction-adjusted free cash flow grew 205% to $326 million with 127% conversion
  • Raised 2026 guidance to $7.16–$7.19 billion sales and $1.75–$1.77 billion operating EBITDA
  • $250 million share repurchase planned for third quarter 2026
  • Aramids divestiture delivered ~$1.2 billion cash, $300 million note and $325 million equity interest

Negative

  • Healthcare & Water Technologies operating EBITDA margin decreased 30 bps to 30.1%
  • Water Technologies experienced weaker demand in the Middle East despite overall segment growth

News Explained

DuPont completed its 1-for-3 reverse stock split, consolidating common shares and proportionally raising the per-share price; the split itself does not change company value.

Market Reaction – DD

-1.39% $139.31
15m delay
-1.39% Vs previous close
$139.31 Last Price
$129.05 $141.56 Day Range
$18.24B Market Cap
0.6x Rel. Volume

Following this news, DD has declined 1.39%, reflecting a mild negative market reaction. Our momentum scanner has triggered 15 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $139.31.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

4.95% was the 24-hour reaction to DuPont's February earnings event, while another prior earnings eve...
Analysis

4.95% was the 24-hour reaction to DuPont's February earnings event, while another prior earnings event recorded -1.21%. That history frames this report's raised guidance; current context also shows net selling by the CEO, a separate risk factor to watch.

Key Figures

Net Sales: $1.8 billion, up 4% GAAP Income: $191 million Operating EBITDA: $448 million, up 6% +5 more
8 metrics
Net Sales $1.8 billion, up 4% Second quarter 2026 versus year-ago period
GAAP Income $191 million Income from continuing operations, second quarter 2026
Operating EBITDA $448 million, up 6% Second quarter 2026 versus second quarter 2025
Adjusted EPS $1.88, up 48% Second quarter 2026 versus second quarter 2025
Operating Cash Flow $400 million Continuing operations, second quarter 2026
Free Cash Flow $326 million, 127% conversion Transaction-adjusted, second quarter 2026
Share Repurchase $250 million Announced intent for the third quarter
Adjusted EPS Guidance $7.24 per share Raised midpoint of full-year 2026 guidance

Previous Earnings Reports

5 past events · Latest: May 05 (Positive)
Same Type Pattern 5 events
Date Event Sentiment 24h Move Catalyst
May 05 First-quarter earnings Positive +8.4% Strong first-quarter results, guidance increase, and accelerated share repurchase
Feb 10 Fourth-quarter earnings Positive +5.0% Full-year results and 2026 outlook accompanied by improved adjusted earnings
Nov 06 Third-quarter earnings Positive -1.2% Higher guidance and substantial capital-return announcements
Aug 05 Second-quarter earnings Positive +2.4% Sales growth, adjusted EPS expansion, and increased full-year guidance
May 02 First-quarter earnings Positive +1.8% Organic sales growth and higher adjusted EPS despite a reported GAAP loss

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

DuPont's earnings announcements have usually aligned with positive price reactions, although one prior earnings event diverged negatively.

Key Terms

organic sales, operating ebitda, adjusted eps, transaction-adjusted free cash flow, +1 more
5 terms
organic sales financial
"organic sales increased 4% versus year-ago period"
Organic sales are the change in a company’s revenue that comes from its existing business operations, excluding effects of acquisitions, divestitures, and currency swings. Think of it like measuring how much a garden grows from the plants you already tended, rather than adding new pots; investors use organic sales to judge whether demand and core business performance are genuinely improving or if growth is driven by one‑time deals or accounting shifts.
operating ebitda financial
"operating EBITDA of $448 million"
Operating EBITDA is a measure of the cash profit a company generates from its core business activities, calculated by taking earnings and adding back interest, taxes, depreciation and amortization while excluding one‑time items and non‑operating income. For investors it acts like checking how much money a store makes from selling its products before financing, taxes and accounting charges, helping compare operational performance across companies and periods.
adjusted eps financial
"adjusted EPS of $1.88"
Adjusted earnings per share (adjusted eps) is a measure of a company's profit per share that has been modified to exclude certain one-time or unusual items, such as costs from restructuring or asset sales. It provides a clearer picture of the company’s core performance by removing events that may distort the usual earnings. Investors use adjusted eps to better understand a company's ongoing profitability and compare it more accurately over time.
transaction-adjusted free cash flow financial
"transaction-adjusted free cash flow of $326 million"
Transaction-adjusted free cash flow measures the cash a company generates from its normal operations after paying for necessary capital spending, but strips out one-time cash effects from deals like acquisitions, divestitures, or large asset sales. For investors it shows the business’s recurring cash-generating ability—like looking at a household’s monthly budget after removing big one-off purchases or windfalls—so you can better judge dividend potential, debt capacity, and underlying financial health.
gics code technical
"Global Industry Classification Standard (GICS) code has changed"
A GICS code is a standardized numeric label that classifies a public company by its industry and sector using the Global Industry Classification Standard. Think of it like a library call number or folder name that groups similar businesses together. Investors use GICS codes to compare companies, build and track sector-based indexes or portfolios, and screen for trends or risks across consistent industry categories.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Exceeds Second Quarter 2026 Guidance

Raises Full Year 2026 Guidance

Second Quarter 2026 Highlights

  • Net Sales of $1.8 billion increased 4%; organic sales increased 4% versus year-ago period
  • GAAP Income from continuing operations of $191 million; operating EBITDA of $448 million
  • GAAP EPS from continuing operations of $1.37; adjusted EPS of $1.88
  • Cash provided by operating activities from continuing operations of $400 million; transaction-adjusted free cash flow of $326 million representing 127% conversion
  • Announces intent to repurchase $250 million of shares in the third quarter
  • Announces the Company's Global Industry Classification Standard (GICS) code has changed to Industrials effective July 31, 2026

WILMINGTON, Del., Aug. 4, 2026 /PRNewswire/ -- DuPont (NYSE: DD) announced its financial results(1) for the second quarter ended June 30, 2026 and raised financial guidance for the full year 2026. 

DuPont Logo

"We delivered another strong quarter, exceeding our financial guidance and demonstrating our focus on consistent execution" said Lori Koch, DuPont Chief Executive Officer. "Mid-single digit organic growth, strong margin expansion, coupled with robust adjusted EPS growth and free cash flow generation underscore the strength of our market-leading businesses and reflect disciplined execution of our strategic priorities, supported by our ongoing focus on excellence and productivity."

"We are delivering on our commitments, creating value for all of our key stakeholders and further strengthening the foundation for sustainable, long-term profitable growth," Koch concluded.

Second Quarter 2026 Consolidated Results(1)


Dollars in millions, except EPS

2Q'26

2Q'25

Change

vs. 2Q'25

Organic Sales (2)

vs. 2Q'25

Net sales

$1,819

$1,749

4 %

4 %

GAAP Income from continuing operations

$191

$24

n.m.


Operating EBITDA(2)

$448

$423

6 %


Operating EBITDA margin(2) %

24.6 %

24.2 %

40 bps


GAAP EPS from continuing operations

$1.37

$0.17

n.m.


Adjusted EPS(2)

$1.88

$1.27

48 %


Cash provided by operating activities – cont. ops.

$400

$74

n.m.


Transaction-adjusted free cash flow(2)

$326

$107

205 %


Net sales

  • Net sales were up 4% on a 4% increase in organic sales.
  • 4% organic sales growth in Healthcare & Water Technologies; 3% organic sales growth in Diversified Industrials.

GAAP Income from continuing operations

  • GAAP Income/GAAP EPS from continuing operations improved on higher segment earnings and lower interest expense and transaction costs.

Operating EBITDA

  • Operating EBITDA increased on organic growth and productivity.

Adjusted EPS

  • Adjusted EPS increased on higher segment earnings, lower net interest expense and a lower tax rate.

Cash provided by operating activities from continuing operations

  • Cash provided by operating activities from continuing operations in the quarter of $400 million, capital expenditures of $76 million and separation-related transaction costs and other payments of $2 million resulted in transaction-adjusted free cash flow and related conversion of $326 million and 127%, respectively.

(1)

Results and cash flows are presented on a continuing operations basis. See page 6 for further information, including the basis of presentation included in this release.

(2)

Organic sales, operating EBITDA, operating EBITDA margin, adjusted EPS, transaction-adjusted free cash flow and transaction-adjusted free cash flow conversion are non-GAAP measures and only reflect continuing operations. See page 6 for further discussion, including a definition of significant items. Reconciliation to the most directly comparable GAAP measure, including details of significant items begins on page 13 of this communication.

 

Second Quarter 2026 Segment Highlights


Healthcare & Water Technologies

Dollars in millions

2Q'26

2Q'25

Change

vs. 2Q'25

Organic Sales(2)

vs. 2Q'25

Net sales

$856

$817

5 %

4 %

Operating EBITDA

$258

$248

4 %


Operating EBITDA margin %

30.1 %

30.4 %

(30) bps


Net sales

  • Net sales increased 5% on organic sales growth of 4% and a currency benefit of 1%.
    • Healthcare Technologies sales up mid-single digits on an organic basis on broad-based growth led by personal protection and biopharma.
    • Water Technologies sales up low-single digits on an organic basis on continued strength in industrial water and semiconductor markets, partially offset by weakness in the Middle East.   

Operating EBITDA

  • Operating EBITDA increased on organic growth and productivity, partially offset by growth investments.
  • Operating EBITDA margin of 30.1% decreased 30 basis points as organic growth and productivity were more than offset by less favorable mix and growth investments.

Diversified Industrials

Dollars in millions

2Q'26

2Q'25

Change

vs. 2Q'25

Organic Sales(2)

vs. 2Q'25

Net sales

$963

$932

3 %

3 %

Operating EBITDA

$213

$199

7 %


Operating EBITDA margin %

22.1 %

21.4 %

70 bps


Net sales

  • Net sales increased 3% on organic sales growth in the quarter.
    • Building Technologies sales up low-single digits on an organic basis due to growth in residential and non-residential construction markets.
    • Industrial Technologies sales up mid-single digits on an organic basis on continued strength in aerospace coupled with growth in electric vehicle applications.

Operating EBITDA

  • Operating EBITDA and margin increased on organic growth, favorable mix and productivity.

2026 Financial Outlook


Dollars in millions, except EPS





2H'26E

Full Year 2026E

Net sales





$3,660 - $3,690

$7,160 - $7,190

Operating EBITDA(2)





$890 - $910

$1,750 - $1,770

Adjusted EPS(2)





$3.65 - $3.80

$7.17 - $7.32

"Our strong execution and market-driven growth continue to translate into higher earnings and free cash flow generation. As a result of our second quarter outperformance, we are again raising the midpoint of our full-year 2026 operating EBITDA guidance to approximately $1.76 billion and adjusted EPS guidance to $7.24 per share, while increasing our expectation for organic sales growth to slightly above 4%," said Antonella Franzen, DuPont Chief Financial Officer.

"With continued strength across healthcare, industrial water, and aerospace end-markets, we expect mid-single digit organic sales growth in the second half and remain focused on driving profitable growth and value creation for shareholders." Franzen concluded.

Conference Call

The Company will host a live webcast of its quarterly earnings conference call with investors to discuss its results and business outlook beginning today at 8:00 a.m. ET. The slide presentation that accompanies the conference call will be posted on the DuPont's Investor Relations Events and Presentations page. A replay of the webcast also will be available on the DuPont's Investor Relations Events and Presentations page following the live event.

About DuPont

DuPont (NYSE: DD) is a global innovation leader, providing advanced solutions that help transform industries and improve everyday life across our key markets of healthcare, water, construction, and industrial. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

DuPontTM and all products, unless otherwise noted, denoted with TM, SM or ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.

Overview

On May 26, 2026, DuPont's Board of Directors announced a reverse stock split of the Company's common stock, par value $0.01 per share, at a ratio of 1-for-3, as well as a reduction in the number of authorized shares of its common stock by a corresponding ratio (the "Reverse Stock Split"), as approved by shareholders. The Reverse Stock Split became effective on June 24, 2026. All share and share-related information presented in these interim Consolidated Financial Statements has been retroactively adjusted in all periods presented to reflect the decreased number of shares resulting from the Reverse Stock Split and related impacts.

On April 1, 2026, DuPont completed the sale of the Aramids business (the "Aramids Business" and the divestiture of the Aramids Business, the "Aramids Divestiture") to Arclin, a portfolio company of an affiliate of TJC LP for pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable in the principal amount of $300 million (the "Aramids Note Receivable") and a non-controlling common equity interest (the "Aramids Equity Consideration"), valued at $325 million, in New Arclin U.S. Holding Corp., which now owns the Arclin global materials business and the Aramids Business. The financial results of the divested Aramids Business are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations, along with comparative periods.

On November 1, 2025, DuPont completed the separation of its semiconductor and interconnect solutions businesses (the "Electronics Business" and the separation of the Electronics Business, the "Electronics Separation") into an independent public company, Qnity Electronics, Inc. ("Qnity"), by way of the distribution to DuPont's stockholders of record as of October 22, 2025 of all the issued and outstanding common stock of Qnity on November 1, 2025 (the "Qnity Distribution"). As a result, the financial results of the divested Electronics Business are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations for all periods.

Cautionary Statement Regarding Forward-looking Statements

Certain statements in this release may be considered forward-looking statements, within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements often contain words such as "expect", "anticipate", "intend", "plan", "believe", "seek", "see", "will", "would", "target", "outlook", "stabilization", "confident", "preliminary", "initial", "continue", "may", "could", "project", "estimate", "forecast" and similar expressions and variations or negatives of these words. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements.

Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to (i) the ability to realize the intended benefits of the Electronics Separation and the Qnity Distribution, including achievement of the intended tax treatment, contractual allocation to, and assumption by Qnity of certain liabilities, including certain legacy liabilities with respect to per- and polyfluoroalkyl substances ("PFAS") and the possibility of disputes, litigation or unanticipated costs in connection with the Electronics Separation and Qnity Distribution; (ii) the impact of the Aramids Divestiture on DuPont's balance sheet, financial condition and future results of operations; (iii) risks and costs related to the impact of the arrangement to share future eligible PFAS costs by and among DuPont, Corteva, Inc. and The Chemours Company, including the outcome of pending or future litigation related to PFAS or PFOA, which includes personal injury claims and natural resource damages claims; the extent and cost of ongoing and potential future remediation obligations; and changes in laws and regulations applicable to PFAS chemicals; (iv) the failure to realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with the Electronics Separation, the Aramids Divestiture and completed and future, if any, divestitures, mergers, acquisitions, and other portfolio management, productivity and infrastructure actions; (v) risks and uncertainties that are outside the Company's control but adversely impact the overall environment in which DuPont, its customers and/or its suppliers operate, including changes in economic, political, regulatory, international trade, geopolitical, military conflicts, capital markets and other external conditions, including pandemics and responsive actions, as well as natural and other disasters or weather-related events; (vi) the ability to offset increases in cost of inputs, including raw materials, energy and logistics; (vii) the risks and uncertainties associated with continuing or expanding geopolitical conflicts or trade disputes or restrictions and responsive actions, new or increased tariffs or export controls, including on exports to China of U.S.-regulated products and technology; (viii) other risks to DuPont's business and operations, including the risk of impairment; (ix) risks and uncertainties in connection with completing the $2 billion share buyback announced on November 6, 2025, including timeline, associated costs and the possibility that the authorization may be suspended or discontinued prior to completion; (x) the ability to realize the intended benefits of the Reverse Stock Split; (xi) the impact of the invalidation of certain tariffs imposed under the International Emergency Economic Powers Act and (xii) other risk factors discussed in DuPont's most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont's consolidated financial condition, results of operations, credit rating or liquidity. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Non-GAAP Financial Measures

Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

This communication includes information that does not conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont's management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these Non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page 12. Non-GAAP measures included in this communication are defined below. The Company has not provided forward-looking U.S. GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of certain future events. These events include, among others, the impact of portfolio changes, including asset sales, mergers, acquisitions, and divestitures; contingent liabilities related to litigation, environmental and indemnifications matters; impairments and discrete tax items. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP results for the guidance period.

Key Terms

Significant Items

Significant items are items that arise outside the ordinary course of business for the Company and includes items for nonconsolidated affiliates, that the Company's management believes may cause misinterpretation of underlying business and investment performance, both historical and future, based on a combination of some or all of the item's size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance. There were no significant items associated with nonconsolidated affiliates recorded for the three and six month periods ended June 30, 2026 and June 30, 2025.

Future Reimbursable Indirect Costs

Indirect costs, such as those related to corporate and shared service functions previously allocated to the separated Electronics Business and Aramids Business, do not meet the criteria for discontinued operations and are reported within continuing operations in all respective periods presented. The Company has, is, will or expects to be reimbursed in accordance with the applicable transition service agreements ("TSAs") for the portion of indirect costs related to activities the Company is, will or expects to undertake on a transitional basis to support a) Qnity not beyond year end 2027 for services and 2040 for site leases and, b) the Aramids Business post the Aramids Divestiture, but not beyond 2028 (such indirect costs "Future Reimbursable Indirect Costs"). Services provided and costs reimbursed in accordance with the applicable TSAs include but are not limited to, costs associated with information technology services/support, product stewardship and regulatory support, facilities services, and shared property lease costs.

Future Reimbursable Indirect Costs do not meet the criteria for discontinued operations and therefore are included in both GAAP Net Income from Continuing Operations and in GAAP Cash provided by operating activities-continuing operations for all periods presented. Future Reimbursable Indirect Costs are excluded from Adjusted Earnings, Operating EBITDA and Transaction-Adjusted Free Cash Flow, each defined below. Such indirect costs that are not subject to future reimbursement are reported within continuing operations in Corporate and are included within Adjusted Earnings, Operating EBITDA, and Cash provided by operating activities-continuing operations.

Corporate DDOB Remediation Costs

Corporate DDOB Remediation Costs are environmental remediation costs, including certain investigate, remediate and restoration costs, associated with discontinued or divested operations, businesses or product lines ("Corporate DDOB Remediation Costs"). DDOB Remediation Costs are excluded from Adjusted Earnings and Operating EBITDA, as defined below, to provide better insight into the underlying business performance of the Company.

Non-GAAP Measure Definitions

Organic Sales

Organic Sales is defined as net sales excluding the impacts of currency and portfolio.

Adjusted Earnings

Adjusted Earnings is defined as income from continuing operations excluding the after-tax impact of significant items, after-tax impact of amortization expense of intangibles, the after-tax impact of non-operating pension / other post employment benefits ("OPEB") credits / costs, Future Reimbursable Indirect Costs and Corporate DDOB Remediation Costs.

Adjusted Earnings is the numerator used in the calculation of Adjusted EPS, as well as the denominator in Adjusted Free Cash Flow Conversion.

Adjusted EPS

Adjusted EPS is defined as Adjusted Earnings per common share - diluted. Management estimates amortization expense in 2026 associated with intangibles to be about $275 million on a pre-tax basis, or approximately $1.54 per share.

Operating EBITDA, EBITDA Margin & Incremental Margin

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., "Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, Corporate DDOB Remediation Costs, and adjusted for significant items. Reconciliations of these measures are provided on the following pages.

Operating EBITDA Margin is defined as Operating EBITDA divided by Net Sales.

Incremental Margin is the change in Operating EBITDA divided by the change in Net Sales for the applicable period.

Adjusted Free Cash Flow & Adjusted Free Cash Flow Conversion

Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and excluding the impact of cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity. As a result, Adjusted Free Cash Flow represents cash that is available to the Company, after investing in its asset base, to fund obligations using the Company's primary source of liquidity, cash provided by operating activities from continuing operations. Management believes Adjusted Free Cash Flow, even though it may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. Management notes that there were no exclusions for items that are unusual in nature and/or infrequent in occurrence for the three and six month periods ended June 30, 2026.

Adjusted Free Cash Flow Conversion is defined as Adjusted Free Cash Flow divided by Adjusted Earnings. Management uses Adjusted Free Cash Flow Conversion as an indicator of our ability to convert earnings to cash.

Transaction Adjusted Free Cash Flow & Transaction Adjusted Free Cash Flow Conversion

Management believes supplemental non-GAAP financial measures including Transaction-Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow Conversion (each defined below) provide an integral view of information on the Company's underlying business performance during this period of transformational change. Management believes the Electronics Separation and Aramids Divestiture collectively represent a significant transformational change for the Company and separation-related transaction cost payments impact comparability to the Company's continuing operations. Management believes Transaction-Adjusted Free Cash Flow, which may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. These non-GAAP financial measures are not intended to represent residual cash flow for discretionary expenditures since other non-discretionary expenditures, such as mandatory debt service requirements, are not deducted from the measure.

Transaction-Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and removing the impact of separation-related transaction costs and other payment and cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity.

Transaction-Adjusted Free Cash Flow Conversion is defined as Transaction-Adjusted Free Cash Flow excluding separation-related transaction costs, divided by Adjusted Earnings.

Separation-related transaction costs and other payments include cash outflows directly associated with the Electronics Separation and the Aramids Divestiture. These costs include advisor and banking fees, payments related to establishing a new capital structure (including fees associated with interest rate swaps), capital expenditures required to facilitate physical asset separation, restructuring payments associated with senior leadership, and Future Reimbursable Indirect Costs, among other expenditures.

Future Reimbursable Indirect Costs are excluded from Adjusted Earnings and Operating EBITDA. To provide comparable data analysis, the Company has also adjusted payments associated with Future Reimbursable Indirect Costs within Separation-related transaction costs and other payments. This adjustment is intended to provide insight into the Company's underlying business performance. For the six months ended June 30, 2026, the Company adjusted $8 million associated with Future Reimbursable Indirect Costs within Separation-related transaction costs and other payments.

Additionally, $2 and $5 million were reflected in Separation-related transaction costs and other payments for the three and six month periods ended June 30, 2026, respectively, for capital expenditures incurred to complete the physical separation of shared locations.

Finally, $6 million of restructuring and short-term incentive program payments to former senior leadership were reflected in Separation-related transaction costs and other payments for the six month period ended June 30, 2026. These payments were reflected in other cash payments as they related to the establishment of the post-spin leadership structure.

DuPont de Nemours, Inc.

Consolidated Statements of Operations



Three Months Ended
June 30,

Six Months Ended

June 30,

In millions, except per share amounts (Unaudited)

2026

2025

2026

2025

Net sales

$    1,819

$    1,749

$    3,500

$    3,361

Cost of sales

1,180

1,143

2,259

2,212

Research and development expenses

42

53

89

103

Selling, general and administrative expenses

269

262

524

496

Amortization of intangibles

68

74

136

149

Restructuring and asset related (benefits) charges - net

(3)

43

39

Acquisition, integration and separation costs

7

55

7

105

Equity in earnings (loss) of nonconsolidated affiliates

9

9

8

(6)

Sundry income (expense) - net

42

(9)

78

91

Interest expense

41

84

81

167

Income from continuing operations before income taxes

$      266

$        78

$      447

$      175

Provision for income taxes on continuing operations

75

54

106

71

Income from continuing operations, net of tax

$      191

$        24

$      341

$      104

(Loss) income from discontinued operations, net of tax

(44)

46

(30)

(615)

Net income (loss)

$      147

$        70

$      311

$     (511)

Net income attributable to noncontrolling interests

4

11

7

19

Net income (loss) available for DuPont common stockholders

$      143

$        59

$      304

$     (530)











Per common share data:





Earnings per common share from continuing operations - basic

$     1.38

$     0.17

$     2.45

$     0.73

(Loss) earnings per common share from discontinued operations - basic

(0.32)

0.25

(0.22)

(4.53)

Earnings (loss) per common share - basic

$     1.05

$     0.42

$     2.23

$    (3.80)

Earnings per common share from continuing operations - diluted

$     1.37

$     0.17

$     2.43

$     0.73

(Loss) earnings per common share from discontinued operations - diluted

(0.32)

0.25

(0.22)

(4.52)

Earnings (loss) per common share - diluted

$     1.05

$     0.42

$     2.22

$    (3.79)






Weighted-average common shares outstanding - basic

135.9

139.6

136.3

139.6

Weighted-average common shares outstanding - diluted

136.8

139.9

137.2

139.9

 

DuPont de Nemours, Inc.

Condensed Consolidated Balance Sheets


In millions, except share amounts (Unaudited)

June 30, 2026

December 31, 2025

Assets



Current Assets



Cash and cash equivalents

$                  1,740

$                    715

Restricted cash and cash equivalents

42

42

Accounts and notes receivable - net

1,751

1,669

Inventories

1,210

1,172

Prepaid and other current assets

113

121

Assets of discontinued operations

1,856

Total current assets

$                  4,856

$                  5,575

Property, plant and equipment - net of accumulated depreciation (June 30,
2026 - $3,694; December 31, 2025 - $3,565)

3,379

3,464

Other Assets



Goodwill

7,840

7,915

Other intangible assets

2,789

2,936

Investments and noncurrent receivables

981

432

Deferred income tax assets

221

282

Deferred charges and other assets

995

971

Total other assets

$                 12,826

$                 12,536

Total Assets

$                 21,061

$                 21,575

Liabilities and Equity



Current Liabilities



Short-term borrowings

$                        —

$                       60

Accounts payable

978

995

Income taxes payable

53

54

Accrued and other current liabilities

970

882

Liabilities of discontinued operations

314

Total current liabilities

$                   2,001

$                  2,305

Long-Term Debt

3,125

3,134

Other Noncurrent Liabilities



Deferred income tax liabilities

295

405

Pension and other post-employment benefits - noncurrent

400

432

Other noncurrent obligations

1,359

1,196

Total other noncurrent liabilities

$                   2,054

$                  2,033

Total Liabilities

$                   7,180

$                  7,472

Commitments and contingent liabilities



Stockholders' Equity



Common stock (authorized 555,555,556 shares of $0.01 par value each;
issued 2026: 135,038,855 shares; 2025: 136,398,482 shares)

1

1

Additional paid-in capital

$                 38,710

38,721

Accumulated deficit

(24,326)

(24,278)

Accumulated other comprehensive loss

(616)

(525)

Total DuPont stockholders' equity

$                 13,769

$                 13,919

Noncontrolling interests

112

184

Total equity

$                 13,881

$                 14,103

Total Liabilities and Equity

$                 21,061

$                 21,575

 

DuPont de Nemours, Inc.

Consolidated Statement of Cash Flows



Six Months Ended June 30,

In millions (Unaudited)

2026

2025

Operating Activities



Net income (loss)

$                311

$               (511)

Loss from discontinued operations

(30)

(615)

Net income from continuing operations

$                341

$                104

Adjustments to reconcile net income to net cash provided by operating activities:



Depreciation and amortization

309

326

Credit for deferred income tax and other tax related items

45

9

(Earnings) losses of nonconsolidated affiliates (in excess of) less than dividends received

(6)

7

Net periodic pension benefit costs

6

2

Periodic benefit plan contributions

(28)

(23)

Restructuring and asset related charges - net

43

39

Interest rate swap gain

(51)

Stock based compensation

27

22

Donatelle contingent earn-out true-up

(14)

(12)

Other net (income) loss

(2)

16

Changes in assets and liabilities, net of effects of acquired and divested companies:



Accounts and notes receivable

(88)

(213)

Inventories

(29)

(51)

Accounts payable

92

(19)

Other assets and liabilities, net

(64)

(5)

Cash provided by operating activities - continuing operations

$                632

$                151

Investing Activities



Capital expenditures

(178)

(172)

Proceeds and adjustments to proceeds from sales of businesses, net of cash divested

1,158

Other investing activities, net

9

7

Cash provided by (used for) investing activities - continuing operations

$                989

$              (165)

Financing Activities



Changes in short-term borrowings

(60)

Purchases of common stock and forward contracts

(275)

Proceeds from issuance of Company stock

107

4

Employee taxes paid for share-based payment arrangements

(22)

(22)

Distributions to noncontrolling interests

(11)

(5)

Dividends paid to stockholders

(163)

(343)

Other financing activities, net

(1)

(7)

Cash used for financing activities - continuing operations

$              (425)

$              (373)

Cash Flows from Discontinued Operations



Cash (used for) provided by operations - discontinued operations

(158)

540

Cash used for investing activities - discontinued operations

(6)

(193)

Cash used for financing activities - discontinued operations

(3)

(17)

Cash (used for) provided by discontinued operations

$              (167)

$                330

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(7)

44

Increase (decrease) in cash, cash equivalents and restricted cash

$             1,022

$                (13)

Cash, cash equivalents and restricted cash from continuing operations, beginning of period

757

1,834

Cash, cash equivalents and restricted cash from discontinued operations, beginning of period

3

58

Cash, cash equivalents and restricted cash at beginning of period

$                760

$             1,892

Cash, cash equivalents and restricted cash from continuing operations, end of period

1,782

1,817

Cash, cash equivalents and restricted cash from discontinued operations, end of period

62

Cash, cash equivalents and restricted cash at end of period

$             1,782

$             1,879

 

DuPont de Nemours, Inc.

Select Segment Information and Non-GAAP Measures


Net Sales by Segment

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30, 2026

Jun 30, 2025

Jun 30, 2026

Jun 30, 2025

Healthcare & Water Technologies

$          856

$          817

$        1,662

$        1,580

Diversified Industrials

963

932

1,838

1,781

Total

$        1,819

$        1,749

$        3,500

$        3,361

 

Net Sales Variance by Segment

Three Months Ended June 30, 2026

Organic Sales

Currency

Portfolio / Other

Total

Percent change from prior year (Unaudited)

Healthcare & Water Technologies

4 %

1 %

— %

5 %

Diversified Industrials

3

3

Total

4 %

— %

— %

4 %

 

Net Sales Variance by Segment

Six Months Ended June 30, 2026

Organic Sales

Currency

Portfolio / Other

Total

Percent change from prior year (Unaudited)

Healthcare & Water Technologies

3 %

2 %

— %

5 %

Diversified Industrials

2

1

3

Total

3 %

1 %

— %

4 %

 

Operating EBITDA by Segment

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30, 2026

Jun 30, 2025

Jun 30, 2026

Jun 30, 2025

Healthcare & Water Technologies

$          258

$          248

$          502

$          471

Diversified Industrials

213

199

413

384

Corporate 1

(23)

(24)

(53)

(72)

Total

$          448

$          423

$          862

$          783

1.

Corporate includes expenses of the Corporate function not allocated to specific business in the Company.



Equity in Earnings (Loss) of Nonconsolidated Affiliates by Segment

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30, 2026

Jun 30, 2025

Jun 30, 2026

Jun 30, 2025

Healthcare & Water Technologies

$             1

$            —

$             2

$            —

Diversified Industrials

(1)

Corporate 1

8

9

7

(6)

Total equity earnings (loss) included in operating EBITDA (GAAP)

$             9

$             9

$             8

$            (6)

1.

Corporate includes the equity interest acquired in the Delrin® Divestiture transaction.

 

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures


Reconciliation of "Income from continuing operations, net of tax" to
"Operating EBITDA"

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30, 2026

Jun 30, 2025

Jun 30, 2026

Jun 30, 2025

Income from continuing operations, net of tax (GAAP)

$         191

$          24

$         341

$         104

+ Provision for income taxes on continuing operations

75

54

106

71

Income from continuing operations before income taxes

$         266

$          78

$         447

$         175

+ Depreciation and amortization

154

166

309

326

 - Interest income 1, 2

24

18

34

35

 + Interest expense 3

41

84

81

166

 - Non-operating pension/OPEB benefit (costs) credits 1

(1)

(1)

2

 - Foreign exchange gains (losses), net 1

4

(14)

14

(17)

+ Future Reimbursable Indirect Costs

25

8

50

+ Corporate DDOB Remediation Costs

6

2

10

5

- Significant items charge

(8)

(72)

(54)

(81)

Operating EBITDA (non-GAAP)

$         448

$         423

$         862

$         783

1.

Included in "Sundry income (expense) - net".

2.

The three and six months ended June 30, 2026 and 2025 excludes accrued interest income earned on employee retention credits. Refer to details of significant items on page 14.

3.

The six months ended June 30, 2025 excludes interest rate swap basis amortization. Refer to details of significant items on page 14.



Reconciliation of "Cash provided by operating activities - continuing
operations" to Adjusted Free Cash Flow
1 , Transaction-Adjusted Free
Cash Flow
1 and calculation of "Adjusted Free Cash Flow Conversion"
and "Transaction-Adjusted Free Cash Flow Conversion"

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30, 2026

Jun 30, 2025

Jun 30, 2026

Jun 30, 2025

Cash provided by operating activities (GAAP) 2 - continuing operations

$       400

$        74

$       632

$       151

Capital expenditures

(76)

(50)

(178)

(172)

Adjusted free cash flow (non-GAAP)

$       324

$        24

$       454

$       (21)

Separation-related transaction cost and other payments3

2

83

19

136

Transaction-adjusted free cash flow (non-GAAP)

$       326

$       107

$       473

$       115






Adjusted earnings (non-GAAP) 4

$       257

$       177

$       483

$       331

Adjusted free cash flow conversion (non-GAAP)

126 %

14 %

94 %

(6) %

Transaction-adjusted free cash flow conversion (non-GAAP)

127 %

60 %

98 %

35 %

1

Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow are calculated on a continuing operations basis for all periods presented. Refer to the definitions of Non-GAAP metrics on pages 7-8 for additional information.

2

Refer to the Consolidated Statement of Cash Flows included in the schedules above for major GAAP cash flow categories as well as further detail relating to the changes in "Cash provided by operating activities - continuing operations" for the six month periods noted.

3

Other payments for the three months ended June 30, 2026 includes $2 million related of separation-related capital expenditures. Other payments for the six months ended June 30, 2026 includes $5 million of separation-related capital expenditures, $6 million related to restructuring and short-term incentive program payments associated with former senior leadership, and $8 million for Future Reimbursable Indirect Costs (as defined in our Non-GAAP definitions).

4

Refer to page 14 for the Non-GAAP reconciliations of Net income from continuing operations available for DuPont common stockholders to Adjusted Earnings (Non-GAAP).

 

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures


Significant Items Impacting Results for the Three Months Ended June 30, 2026

In millions, except per share amounts (Unaudited)

Pretax 1

Net
Income
2

EPS 3

Income Statement Classification

Reported earnings (GAAP)

$     266

$     187

$    1.37


Less: Significant items





Acquisition, integration & separation costs

(7)

(5)

(0.04)

Acquisition, integration and separation costs

Restructuring and asset related benefits - net

3

Restructuring and asset related charges – net

Other benefits (credits), net 4

(4)

(3)

(0.02)

Sundry income (expense) - net; Selling, general and administrative expenses

Income tax items 5

(3)

(0.02)

Provision for income taxes on continuing operations

Total significant items

$      (8)

$     (11)

$   (0.08)


Less: Amortization of intangibles

(68)

(53)

(0.39)

Amortization of intangibles

Less: Non-op pension / OPEB benefit costs

(1)

(1)

(0.01)

Sundry income (expense) - net

Less: Corporate DDOB remediation costs

(6)

(5)

(0.03)

Selling, general and administrative expenses

Adjusted earnings (non-GAAP)

$     349

$     257

$    1.88


 

Significant Items Impacting Results for the Three Months Ended June 30, 2025

In millions, except per share amounts (Unaudited)

Pretax 1

Net
Income
2

EPS 3

Income Statement Classification

Reported earnings (GAAP)

$      78

$      24

$    0.17


Less: Significant items





Acquisition, integration and separation costs

(55)

(46)

(0.32)

Acquisition, integration and separation costs

Restructuring and asset related benefits - net

1

Restructuring and asset related charges - net

Interest rate swap mark-to-market loss 6

(27)

(21)

(0.15)

Sundry income (expense) - net

Other benefits (credits), net 7

10

8

0.06

Sundry income (expense) - net

Income tax items 8

(18)

(0.13)

Provision for income taxes on continuing operations

Total significant items

$     (72)

$     (76)

$   (0.54)


Less: Amortization of intangibles

(74)

(58)

(0.42)

Amortization of intangibles

Less: Non-op pension / OPEB benefit credits

Sundry income (expense) - net

Less: Future reimbursable indirect costs

(25)

(19)

(0.14)

Selling, general and administrative expenses

Less: Corporate DDOB remediation costs

(2)

Selling, general and administrative expenses

Adjusted earnings (non-GAAP)

$     251

$     177

$    1.27


1.

Income (loss) from continuing operations before income taxes.

2.

Net income (loss) from continuing operations available for DuPont common stockholders. The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

3.

Earnings (loss) per common share from continuing operations - diluted.

4.

Includes benefits related to an adjustment of the Donatelle contingent earn-out liability ($8 million pre-tax benefit) and legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($7 million pre-tax cost), and legal costs associated with personal injury cases associated with Corian® Quartz, a product within the Diversified Industrials segment ($8 million pre-tax cost).

5.

Reflects the net impact of a valuation allowance release in Europe and a deferred tax asset reversal in the U.S.

6.

The three months ended June 30, 2025 includes non-cash mark-to-market loss related to the 2022 Swaps and 2024 Swaps and the interest settlement loss on the 2022 Swaps.

7.

Reflects the accrued interest earned on employee retention credits ($3 million pre-tax benefit), benefits related to an adjustment of the Donatelle contingent earn-out liability ($12 million pre-tax benefit) and legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($5 million pre-tax cost).

8.

Reflects the income tax impact of certain internal restructurings related to the Electronics Separation.

 

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures

 


Significant Items Impacting Results for the Six Months Ended June 30, 2026

In millions, except per share amounts (Unaudited)

Pretax 1

Net
Income
2

EPS 3

Income Statement Classification

Reported earnings (GAAP)

$     447

$     334

$    2.43


Less: Significant items





Acquisition, integration & separation costs

(7)

(5)

(0.04)

Acquisition, integration and separation costs

Restructuring and asset related charges - net

(43)

(36)

(0.26)

Restructuring and asset related charges - net

Other benefits (credits), net 4

(4)

(3)

(0.02)

Sundry income (expense) - net; Selling, general and administrative expenses

Income tax items 5

15

0.11

Provision for income taxes on continuing operations

Total significant items

$     (54)

$     (29)

$   (0.21)


Less: Amortization of intangibles

(136)

(105)

(0.77)

Amortization of intangibles

Less: Non-op pension / OPEB benefit costs

(1)

(1)

(0.01)

Sundry income (expense) - net

Less: Future reimbursable indirect costs

(8)

(6)

(0.04)

Selling, general and administrative expenses

Less: Corporate DDOB remediation costs

(10)

(8)

(0.06)

Selling, general and administrative expenses

Adjusted earnings (non-GAAP)

$     656

$     483

$    3.52


 

Significant Items Impacting Results for the Six Months Ended June 30, 2025

In millions, except per share amounts (Unaudited)

Pretax 1

Net
Income
2

EPS 3

Income Statement Classification

Reported earnings (GAAP)

$     175

$     102

$    0.73


Less: Significant items





Acquisition, integration and separation costs

(105)

(89)

(0.63)

Acquisition, integration and separation costs

Restructuring and asset related charges - net

(39)

(32)

(0.23)

Restructuring and asset related charges - net

Interest rate swap mark-to-market loss 6

50

39

0.28

Sundry income (expense) - net; Interest expense

Other benefits (credits), net 7

13

11

0.08

Sundry income (expense) - net

Income tax items 8

(2)

(0.02)

Provision for income taxes on continuing operations

Total significant items

$     (81)

$     (73)

$   (0.52)


Less: Amortization of intangibles

(149)

(117)

(0.84)

Amortization of intangibles

Less: Non-op pension / OPEB benefit credits

2

2

0.01

Sundry income (expense) - net

Less: Future reimbursable indirect costs

(50)

(39)

(0.28)

Selling, general and administrative expenses

Less: Corporate DDOB remediation costs

(5)

(2)

(0.01)

Selling, general and administrative expenses

Adjusted earnings (non-GAAP)

$     458

$     331

$    2.37


1.

Income (loss) from continuing operations before income taxes.

2.

Net income (loss) from continuing operations available for DuPont common stockholders. The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

3.

Earnings (loss) per common share from continuing operations - diluted.

4.

Reflects the accrued interest earned on employee retention credits ($3 million pre-tax benefit), benefits related to an adjustment of the Donatelle contingent earn-out liability ($14 million pre-tax benefit), legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($10 million pre-tax cost), and legal costs associated with personal injury cases associated with Corian® Quartz, a product within the Diversified Industrials segment ($11 million pre-tax cost).

5.

Reflects the 2026 income tax benefit primarily the result of a discrete tax benefit relating to a change in tax classification of a non-U.S. legal entity ($20 million pre-tax benefit).

6.

The six months ended June 30, 2025 includes non-cash mark-to-market gain related to the 2022 Swaps and 2024 Swaps and the interest settlement loss on the 2022 Swaps. The six months ended June 30, 2025 also includes basis amortization on the 2022 Swaps ($1 million pre-tax, reflected in "Interest expense" within the Consolidated Statements of Operations).

7.

Reflects the accrued interest earned on employee retention credits ($6 million pre-tax benefit), benefits related to an adjustment of the Donatelle contingent earn-out liability ($12 million pre-tax benefit), legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($5 million pre-tax cost).

8.

Reflects the income tax impact of certain internal restructurings related to the Electronics Separation.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dupont-reports-second-quarter-2026-results-302841628.html

SOURCE DuPont

FAQ

How did DuPont (DD) perform in the second quarter of 2026?

DuPont reported solid second quarter 2026 growth, with net sales up 4% to $1.819 billion and adjusted EPS up 48% to $1.88. According to DuPont, operating EBITDA reached $448 million and transaction-adjusted free cash flow rose to $326 million.

Did DuPont (DD) raise its full-year 2026 guidance after Q2 results?

Yes. DuPont raised its full-year 2026 guidance to net sales of $7.16–$7.19 billion, operating EBITDA of $1.75–$1.77 billion, and adjusted EPS of $7.17–$7.32. According to DuPont, this reflects stronger organic sales growth, slightly above 4% for 2026.

What share repurchase plans did DuPont (DD) announce with its Q2 2026 earnings?

DuPont announced its intent to repurchase $250 million of shares in the third quarter of 2026. According to DuPont, this buyback follows strong earnings, margin expansion and transaction-adjusted free cash flow of $326 million in the second quarter of 2026.

What were the key segment results for DuPont (DD) in Q2 2026?

Healthcare & Water Technologies delivered net sales of $856 million (up 5%), while Diversified Industrials reported $963 million (up 3%). According to DuPont, Healthcare & Water Technologies margin was 30.1%, and Diversified Industrials operating EBITDA margin improved to 22.1% in Q2 2026.

What was DuPont’s 2026 second-half outlook following Q2 2026 earnings?

For the second half of 2026, DuPont expects net sales of $3.66–$3.69 billion, operating EBITDA of $890–$910 million, and adjusted EPS of $3.65–$3.80. According to DuPont, guidance assumes mid-single digit organic sales growth in the second half.

What major portfolio changes did DuPont (DD) highlight in its Q2 2026 report?

DuPont completed the Aramids business sale on April 1, 2026, receiving ~$1.2 billion cash, a $300 million note and $325 million equity. According to DuPont, it also previously separated its Electronics business into Qnity and executed a 1-for-3 reverse stock split.

How strong was DuPont’s cash flow in the second quarter of 2026?

DuPont generated cash from operating activities from continuing operations of $400 million in Q2 2026 and transaction-adjusted free cash flow of $326 million. According to DuPont, this represented a 205% year-over-year increase and a 127% free cash flow conversion rate.